Using larger-scale cohorts of GC patients, future studies should clarify the role of the combination of PD-L1 expression and the presence of TILs in the tumor microenvironment as a putative prognostic indicator and as a predictive biomarker for the application of anti-PD-1/PD-L1 therapy. The gene discussed is PDCD1; the disease is gastric cancer.